Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Overview
Nutriband Inc is a Florida-based pharmaceutical company specializing in the development of transdermal drug delivery systems that incorporate advanced abuse-deterrent technologies. Its core business revolves around transdermal pharmaceutical products engineered to mitigate the risks of drug abuse, misuse, diversion, and accidental exposure, with a special emphasis on addressing the global opioid crisis. Utilizing proprietary technology that integrates aversive agents into transdermal patches, Nutriband is dedicated to improving patient safety while ensuring essential medications remain accessible for those in need.
Advanced Abuse-Deterrent Technology
The company’s flagship innovation, AVERSA technology, is designed to deter the oral abuse of potent drugs by utilizing taste aversion methods. This technology can be incorporated into various transdermal patches, a critical step toward preventing accidental exposures—particularly in vulnerable populations such as young children. The patented approach provides an additional safeguard by making the potential for abuse less appealing, thereby enhancing the overall safety profile of drugs with abuse potential.
Business Model and Operations
Nutriband Inc generates revenue primarily through the sale of consumer transdermal and coated products, as well as through contract manufacturing services provided by its wholly owned subsidiary, Pocono Pharma. The company leverages its strategic partnerships with top industry players to extend its market reach, including engagements with major retailers and established pharmaceutical manufacturing organizations. This diversified revenue approach not only supports the current portfolio but also positions Nutriband as a flexible partner in both the healthcare and contract manufacturing sectors.
Strategic Partnerships and Intellectual Property
A cornerstone of Nutriband’s success is its robust global intellectual property portfolio, which spans across more than 40 countries including the United States, Europe, Japan, and Australia. Such extensive protection underpins its innovative AVERSA technology and provides a competitive edge in the increasingly critical field of abuse-deterrent transdermal systems. Strategic alliances with industry experts such as Kindeva Drug Delivery further reinforce its position by ensuring that large-scale manufacturing processes align with FDA guidelines and international industry standards.
Market Position and Industry Significance
Operating at the nexus of pharmaceutical innovation and patient safety, Nutriband Inc is positioned distinctively in the competitive landscape of transdermal drug delivery systems. Its strategic focus on developing abuse-deterrent products addresses a significant unmet need in the market, particularly in the context of managing opioid-related risks without compromising therapeutic access. Through its commitment to evolving industry standards and enhancing product safety, Nutriband has established itself as a forward-thinking entity within a critical market segment.
Product Portfolio and Future Applications
While its lead product, an abuse-deterrent fentanyl patch, remains at the forefront of its development efforts, Nutriband is actively expanding its portfolio to include additional transdermal therapies. By integrating its core AVERSA technology across multiple product lines, the company aims to address a wide spectrum of medications with abuse potential, including opioids and stimulants. This strategy not only diversifies its technology applications but also solidifies its reputation as an innovator in transdermal pharmaceutical solutions.
Commitment to Safety and Regulatory Compliance
At the heart of Nutriband’s mission is a dedication to enhancing patient safety through rigorous research, development, and close adherence to regulatory standards. The company emphasizes clear, methodical approaches that streamline market entry while upholding the highest safety measures. This balance of innovation and compliance is critical in a market where the prevention of misuse and accidental exposure is of paramount concern.
Overall, Nutriband Inc exemplifies a strategic blend of innovative product development, methodical market expansion, and a steadfast commitment to patient safety. Its robust technology platform, significant IP portfolio, and established industry partnerships underscore its role as a key contributor to the evolution of abuse-deterrent pharmaceutical products.
Nutriband Inc. (NTRB, NTRBW) announced a 7:6 forward stock split effective at 12:01 AM on August 15, 2022. Shareholders will receive seven shares for every six shares held, maintaining the par value. CEO Gareth Sheridan emphasized the company's commitment to creating shareholder value following recent milestones. Nutriband is focused on developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing its AVERSA technology. The company acknowledges various risks involved in its development and regulatory processes.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced a favorable Final Judgment allowing the cancellation of 1.2 million shares, approximately 15% of its outstanding shares, previously issued for an acquisition now rescinded. This cancellation, expected to be processed within one business day, will reduce Nutriband's total outstanding shares to 6.6 million. The company is focused on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing the AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NASDAQ:NTRBW) has announced the opening of a new branch in Quito, Ecuador, aimed at expanding its product offerings in the region through product registration and contract services. CEO Gareth Sheridan emphasized this move as a significant step towards enhancing revenue opportunities and building relationships. The company specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA® technology. This expansion marks a strategic initiative to penetrate the South American market.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) is set to be featured in an interview on Bloomberg TV on July 23 at 7 p.m. ET. CEO Gareth Sheridan will discuss revenue growth, partnerships, and the company's role in addressing the opioid crisis with its innovative AVERSA technology. The company specializes in transdermal pharmaceutical products, primarily an abuse-deterrent fentanyl patch. This broadcast reaches approximately 73 million households in the U.S., enhancing visibility for Nutriband's initiatives and offerings.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a favorable court verdict regarding its 2017 acquisition of Advanced Health Brands, allowing the recovery of 4.8 million shares that had been issued as part of the deal. After a reverse split in 2018, this recovery translates to approximately 1.2 million shares, or 15% of the company’s total outstanding shares. This successful legal outcome is expected to reduce Nutriband's total outstanding shares, positively impacting shareholder value.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) endorses the updated CDC guidelines for opioid prescription, advocating for comprehensive pain management that includes responsible opioid use. The draft guidelines have received positive feedback, suggesting a need to ease restrictions for patients suffering from severe pain. Nutriband's AVERSA™ technology aims to prevent opioid abuse through its unique transdermal patches. This could lead to significant sales, estimated at $80M - $200M within five years. The company holds broad patent protections for this technology globally.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that CEO Gareth Sheridan will be featured on The RedChip Money Report on Bloomberg TV, airing on May 28 at 7 p.m. ET. This program, focused on small-cap investing, reaches approximately 73 million homes in the U.S. Nutriband is developing transdermal pharmaceutical products, including an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The company aims to prevent misuse and accidental exposure to drugs with abuse potential. For more information, visit www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has been invited to present at the Emerging Growth Conference on May 25, 2022, at 2:00 p.m. Eastern time. This live online event allows shareholders and investors to engage with CEO Gareth Sheridan in real time. The presentation will last 30 minutes and include a Q&A session. An archived webcast will be available for those who cannot attend live. Nutriband focuses on developing transdermal pharmaceutical products, including an abuse deterrent fentanyl patch using AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported $234,000 in new contract manufacturing orders through its subsidiary, Pocono Pharma, marking significant revenue growth. This amount surpasses the total revenue for Q2 2021. CEO Gareth Sheridan emphasized the importance of expanding revenue opportunities while advancing the development of their AVERSA abuse deterrent fentanyl patch. The company is focused on enhancing its portfolio of transdermal pharmaceutical products, indicated by the recent order volume.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced its subsidiary, Active Intelligence LLC, has registered as a Class I medical device manufacturer with the FDA. This registration enables the production and distribution of its proprietary AI Tape, aimed at the kinesiology tape market, valued over $5 billion and growing at a 6.8% CAGR. CEO Gareth Sheridan emphasized this milestone will drive commercial sales and open avenues for contract manufacturing. Active Intelligence is also developing medicated kinesiology tapes for sports injury recovery.